Sanara MedTech (NASDAQ:SMTI – Get Free Report) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $29.30 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.
Sanara MedTech (NASDAQ:SMTI – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $28.95 million. Sanara MedTech had a positive return on equity of 29.72% and a negative net margin of 29.15%.
Sanara MedTech Stock Up 1.7%
SMTI opened at $32.10 on Tuesday. Sanara MedTech has a 12 month low of $16.05 and a 12 month high of $35.52. The business has a 50-day moving average of $34.20 and a two-hundred day moving average of $25.79. The company has a debt-to-equity ratio of 5.86, a current ratio of 2.58 and a quick ratio of 2.30. The stock has a market capitalization of $295.00 million, a price-to-earnings ratio of 146.96 and a beta of 1.23.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on SMTI
Sanara MedTech Company Profile
Sanara MedTech Inc is a medical technology company focused on developing, commercializing and distributing products used in wound care, surgical soft-tissue repair and tissue regeneration. The company serves healthcare providers treating acute, chronic and complex wounds, as well as patients requiring surgical tissue management.
Sanara’s product portfolio includes advanced wound-care and tissue-repair technologies such as CellerateRX products, FORTIFY tissue-repair products and other regenerative medicine solutions.
See Also
- Five stocks we like better than Sanara MedTech
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
